S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers

Merck & Co., Inc. - MRK Stock Forecast, Price & News

$102.94
-0.52 (-0.50%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$102.48
$103.79
50-Day Range
$102.94
$114.84
52-Week Range
$72.88
$115.49
Volume
11.21 million shs
Average Volume
8.64 million shs
Market Capitalization
$260.99 billion
P/E Ratio
18.03
Dividend Yield
2.84%
Price Target
$115.41

Merck & Co., Inc. MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
12.1% Upside
$115.41 Price Target
Short Interest
Healthy
0.64% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.27mentions of Merck & Co., Inc. in the last 14 days
Based on 34 Articles This Week
Insider Trading
Selling Shares
$34.86 M Sold Last Quarter
Proj. Earnings Growth
25.11%
From $6.85 to $8.57 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.54 out of 5 stars

Medical Sector

2nd out of 1,028 stocks

Pharmaceutical Preparations Industry

1st out of 501 stocks

MRK stock logo

About Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. is a US-based multinational pharmaceutical and healthcare company. It was officially founded in 1891 as the US arm of Merck Group, headquartered in Germany. Merck Group was founded in 1668 when Friedrick Jacob Merck purchased a pharmacy in Darmstadt, Germany. The company transformed from a pharmacy into a drug manufacturer in 1827 with the commercialization of morphine and the perfection of the manufacturing process. The company will later gain recognition for isolating and commercializing the manufacture of cocaine as well.

Merck Group sent Theodore Weicker to New York as its representative in 1889 and he quickly began to set up operations. The original investment of $200,000 resulted in a facility in lower Manhattan and the addition of Merck family member George Merck to the project. They began operations in 1891 and were in business as the US branch of Merck Group until 1917 and the onset of World War I.

World War I brought about the Trading With The Enemy Act of 1917 and the nationalization of Merck Group’s US operations. Those operations were repurchased at a government auction only 2 years later with the help of Goldman Sachs and Lehman Brothers, but the split was done. The company retained rights to the Merck name in the US but remained independent. One of many noteworthy achievements in the post-War period is the discovery of streptomycin, which was revolutionary in treating tuberculosis.

In 1953 the company merged with Sharp& Dohme to form the then 2nd largest US drug manufacturer. The merger brought smallpox vaccines to the portfolio and opened a new avenue of research for the business. Since then, advancements in vaccine technology include treatments for mumps and chickenpox. Other notable advancements include the discovery of statins as a cholesterol inhibitor and work in veterinary medicine.

Today, Merck & Co operates through 2 segments and under 2 different names with a headquarters in Kenilworth, NJ.  The company operates as Merck & Co in the US and as Merck Sharp & Dohme outside the US and Canada. The 2 segments are Pharmaceutical and Animal Health. Revenue topped $49 billion in 2022 and employed more than 68,000 people. The company has 8 research facilities near major university systems, including 7 in the US and 1 in the UK. As of 2022, the company had 82 pipeline products in Phase 2 trials, 30 in Phase 3 trials and 3 under review.

The Pharmaceutical segment researches discover and commercializes human health products in several areas of medicine. These include but are not limited to oncology, acute care, immunology, neuroscience, virology, cardiovascular, and diabetes. This segment has 6 blockbuster drugs as of late 2022, with each generating more than $1 billion in revenue. The leading treatments are Keytruda for treating cancer-related immune conditions, Gardisil which is a vaccine for HPV and Januvia for treating Type-II diabetes. The Animal Health segment discovers, develops, manufactures, and markets veterinary healthcare products and services. Both segments sell to healthcare facilities and distributors.

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Stock News Headlines

Cassava Sciences Stock Undervalued with Its $124 Price Target? (MRK)
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Is the Pain Over for Baudax Bio Investors after a 70% Spike? (MRK)
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Merck & Co., Inc. (NYSE:MRK) Price Target Cut to $120.00
Merck Full Year 2022 Earnings: EPS Misses Expectations
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Merck (MRK) Q4 2022 Earnings Call Transcript
Merck (MRK) Beats Q4 Earnings and Revenue Estimates
Merck (MRK) to Report Q4 Earnings: What's in the Cards?
Is Merck & Co. (MRK) a Long-Term Bet?
See More Headlines
Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Company Calendar

Ex-Dividend for 1/9 Dividend
12/14/2022
Dividend Payable
1/09/2023
Last Earnings
2/02/2023
Today
2/05/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
68,000
Year Founded
1891

Price Target and Rating

Average Stock Price Forecast
$115.41
High Stock Price Forecast
$135.00
Low Stock Price Forecast
$98.00
Forecasted Upside/Downside
+12.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
17 Analysts

Profitability

Net Income
$13.05 billion
Pretax Margin
27.74%

Debt

Sales & Book Value

Annual Sales
$59.28 billion
Cash Flow
$7.32 per share
Book Value
$15.14 per share

Miscellaneous

Outstanding Shares
2,535,400,000
Free Float
2,528,043,000
Market Cap
$260.99 billion
Optionable
Optionable
Beta
0.36

Social Links


Key Executives

  • Robert M. DavisRobert M. Davis
    Chairman & chief executive officer
  • Caroline A. LitchfieldCaroline A. Litchfield
    Chief Financial Officer & Executive Vice President
  • Dave Williams
    EVP, Chief Information & Digital Officer
  • Lisa LeCointe-Cephas
    Chief Ethics & Compliance Officer, SVP
  • Richard R. DeLucaRichard R. DeLuca
    Executive Vice President & President-Animal Health













MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRK shares.
View MRK analyst ratings
or view top-rated stocks.

What is Merck & Co., Inc.'s stock price forecast for 2023?

17 Wall Street research analysts have issued 12 month price targets for Merck & Co., Inc.'s shares. Their MRK share price forecasts range from $98.00 to $135.00. On average, they anticipate the company's stock price to reach $115.41 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price.
View analysts price targets for MRK
or view top-rated stocks among Wall Street analysts.

How have MRK shares performed in 2023?

Merck & Co., Inc.'s stock was trading at $110.95 at the start of the year. Since then, MRK shares have decreased by 7.2% and is now trading at $102.94.
View the best growth stocks for 2023 here
.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a decline in short interest in December. As of December 30th, there was short interest totaling 17,210,000 shares, a decline of 16.1% from the December 15th total of 20,510,000 shares. Based on an average trading volume of 9,590,000 shares, the days-to-cover ratio is presently 1.8 days.
View Merck & Co., Inc.'s Short Interest
.

When is Merck & Co., Inc.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our MRK earnings forecast
.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Thursday, February, 2nd. The company reported $1.62 earnings per share for the quarter, topping analysts' consensus estimates of $1.56 by $0.06. The firm earned $13.83 billion during the quarter, compared to the consensus estimate of $13.66 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 44.27% and a net margin of 24.49%. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.80 EPS.
Read the conference call transcript
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, January 24th. Investors of record on Wednesday, March 15th will be given a dividend of $0.73 per share on Monday, April 10th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend is Tuesday, March 14th.
Read our dividend analysis for MRK
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.92 per share and currently has a dividend yield of 2.82%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 51.14%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MRK will have a dividend payout ratio of 34.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided earnings per share guidance of $6.80-$6.95 for the period, compared to the consensus estimate of $7.36. The company issued revenue guidance of $57.20 billion-$58.70 billion, compared to the consensus revenue estimate of $58.07 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.48%), Sumitomo Mitsui Trust Holdings Inc. (0.33%), DekaBank Deutsche Girozentrale (0.19%), New York State Common Retirement Fund (0.19%), Capital Wealth Planning LLC (0.14%) and Sarasin & Partners LLP (0.12%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Johannes Jacobus Oosthuizen, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay, Steven Mizell and Wendell P Weeks.
View institutional ownership trends
.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $102.94.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $260.99 billion and generates $59.28 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $5.71 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

The company employs 68,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 2/5/2023 by MarketBeat.com Staff